Published in Endocrinology on August 04, 2005
Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med (2008) 9.19
FGF23 induces left ventricular hypertrophy. J Clin Invest (2011) 7.22
Regulation of fibroblast growth factor-23 signaling by klotho. J Biol Chem (2006) 6.50
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
The associations of fibroblast growth factor 23 and uncarboxylated matrix Gla protein with mortality in coronary artery disease: the Heart and Soul Study. Ann Intern Med (2010) 4.89
Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation (2009) 4.87
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest (2007) 2.79
Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem (2011) 2.46
FGF23 neutralization improves chronic kidney disease-associated hyperparathyroidism yet increases mortality. J Clin Invest (2012) 2.41
The FGF23-Klotho axis: endocrine regulation of phosphate homeostasis. Nat Rev Endocrinol (2009) 2.26
Endocrine functions of bone in mineral metabolism regulation. J Clin Invest (2008) 2.19
Circulating fibroblast growth factor 23 in patients with end-stage renal disease treated by peritoneal dialysis is intact and biologically active. J Clin Endocrinol Metab (2009) 2.12
In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J (2008) 2.03
Regulation and function of the FGF23/klotho endocrine pathways. Physiol Rev (2012) 1.97
The emerging role of the fibroblast growth factor-23-klotho axis in renal regulation of phosphate homeostasis. J Endocrinol (2007) 1.81
Fibroblast growth factor 23 and Klotho: physiology and pathophysiology of an endocrine network of mineral metabolism. Annu Rev Physiol (2013) 1.78
FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. Am J Physiol Renal Physiol (2009) 1.70
Current understanding of klotho. Ageing Res Rev (2008) 1.64
Klotho and aging. Biochim Biophys Acta (2009) 1.58
Assessment of 24,25(OH)2D levels does not support FGF23-mediated catabolism of vitamin D metabolites. Kidney Int (2012) 1.57
Pathogenic role of Fgf23 in Dmp1-null mice. Am J Physiol Endocrinol Metab (2008) 1.55
FGF-23-Klotho signaling stimulates proliferation and prevents vitamin D-induced apoptosis. J Cell Biol (2008) 1.53
FGF23-mediated regulation of systemic phosphate homeostasis: is Klotho an essential player? Am J Physiol Renal Physiol (2008) 1.46
Role of FGF23 in vitamin D and phosphate metabolism: implications in chronic kidney disease. Exp Cell Res (2012) 1.41
Skeletal secretion of FGF-23 regulates phosphate and vitamin D metabolism. Nat Rev Endocrinol (2012) 1.37
Klotho. Pflugers Arch (2010) 1.34
Premature aging in klotho mutant mice: cause or consequence? Ageing Res Rev (2007) 1.29
FGFR3 and FGFR4 do not mediate renal effects of FGF23. J Am Soc Nephrol (2008) 1.28
FGF23 is a novel regulator of intracellular calcium and cardiac contractility in addition to cardiac hypertrophy. Am J Physiol Endocrinol Metab (2013) 1.26
Vitamin D: Metabolism, Molecular Mechanism of Action, and Pleiotropic Effects. Physiol Rev (2016) 1.25
FGF-23 as a predictor of renal outcome in diabetic nephropathy. Clin J Am Soc Nephrol (2010) 1.22
Common genetic variants associate with serum phosphorus concentration. J Am Soc Nephrol (2010) 1.20
Compound deletion of Fgfr3 and Fgfr4 partially rescues the Hyp mouse phenotype. Am J Physiol Endocrinol Metab (2010) 1.19
Molecular mechanisms of fibroblast growth factor signaling in physiology and pathology. Cold Spring Harb Perspect Biol (2013) 1.10
Calcium regulates FGF-23 expression in bone. Endocrinology (2013) 1.09
Fibroblast growth factor 23 (FGF23) and alpha-klotho stimulate osteoblastic MC3T3.E1 cell proliferation and inhibit mineralization. Calcif Tissue Int (2011) 1.07
Biological activity of FGF-23 fragments. Pflugers Arch (2007) 1.03
Mineral metabolism and aging: the fibroblast growth factor 23 enigma. Curr Opin Nephrol Hypertens (2007) 1.02
Skeletal overgrowth is mediated by deficiency in a specific isoform of fibroblast growth factor receptor 3. Proc Natl Acad Sci U S A (2007) 0.99
Effects of gonadal steroid withdrawal on serum phosphate and FGF-23 levels in men. Bone (2006) 0.97
Cardiovascular Risk Factors and Chronic Kidney Disease-FGF23: A Key Molecule in the Cardiovascular Disease. Int J Hypertens (2014) 0.97
Conversion of a paracrine fibroblast growth factor into an endocrine fibroblast growth factor. J Biol Chem (2012) 0.96
Phosphate: known and potential roles during development and regeneration of teeth and supporting structures. Birth Defects Res C Embryo Today (2008) 0.90
Insights from genetic disorders of phosphate homeostasis. Semin Nephrol (2013) 0.81
FGF23: its role in renal bone disease. Pediatr Nephrol (2006) 0.79
A systems biology preview of the relationships between mineral and metabolic complications in chronic kidney disease. Semin Nephrol (2013) 0.78
Fibroblast growth factor 23 (FGF23) gene polymorphism in children with Kawasaki syndrome (KS) and susceptibility to cardiac abnormalities. Ital J Pediatr (2013) 0.77
Klotho in cardiovascular disease: Current and future perspectives. World J Biol Chem (2015) 0.77
Conditional Deletion of Fgfr1 in the Proximal and Distal Tubule Identifies Distinct Roles in Phosphate and Calcium Transport. PLoS One (2016) 0.76
Convergent Signaling Pathways Regulate Parathyroid Hormone and Fibroblast Growth Factor-23 Action on NPT2A-mediated Phosphate Transport. J Biol Chem (2016) 0.75
Ironing out the cross talk between FGF23 and inflammation. Am J Physiol Renal Physiol (2016) 0.75
Molecular bases of diseases characterized by hypophosphatemia and phosphaturia: new understanding. Clin Pediatr Endocrinol (2006) 0.75
Post-renal transplantation hypophosphatemia. Pediatr Nephrol (2009) 0.75
Multiple faces of fibroblast growth factor-23. Curr Opin Nephrol Hypertens (2016) 0.75
Cardiac actions of fibroblast growth factor 23. Bone (2016) 0.75
Klotho modulates FGF23-mediated NO synthesis and oxidative stress in human coronary artery endothelial cells. Pflugers Arch (2016) 0.75
Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods (2001) 414.27
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Fibroblast growth factor receptor 3 is a negative regulator of bone growth. Cell (1996) 7.70
Receptor specificity of the fibroblast growth factor family. J Biol Chem (1996) 7.58
Autosomal dominant hypophosphataemic rickets is associated with mutations in FGF23. Nat Genet (2000) 7.41
Targeted ablation of Fgf23 demonstrates an essential physiological role of FGF23 in phosphate and vitamin D metabolism. J Clin Invest (2004) 7.00
FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J Bone Miner Res (2003) 6.81
Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc Natl Acad Sci U S A (2001) 6.70
Structural and functional diversity in the FGF receptor multigene family. Adv Cancer Res (1993) 4.67
Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development (2003) 4.63
Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab (2002) 4.17
FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease. Genes Dev (2002) 4.16
Murine FGFR-1 is required for early postimplantation growth and axial organization. Genes Dev (1994) 3.97
Transgenic mice expressing fibroblast growth factor 23 under the control of the alpha1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology (2004) 3.89
A restricted cytoplasmic region of IL-2 receptor beta chain is essential for growth signal transduction but not for ligand binding and internalization. Cell (1989) 3.70
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest (2003) 3.60
Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int (2001) 3.44
An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. Hum Mol Genet (2004) 3.42
Heparin is required for cell-free binding of basic fibroblast growth factor to a soluble receptor and for mitogenesis in whole cells. Mol Cell Biol (1992) 3.41
Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol (2004) 3.23
Regulation of fibroblastic growth factor 23 expression but not degradation by PHEX. J Biol Chem (2003) 2.91
Fibroblast growth factor-23 relationship to dietary phosphate and renal phosphate handling in healthy young men. J Clin Endocrinol Metab (2004) 2.83
The cytoplasmic region of the erythropoietin receptor contains nonoverlapping positive and negative growth-regulatory domains. Mol Cell Biol (1991) 2.77
FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun (2004) 2.52
FGFs, their receptors, and human limb malformations: clinical and molecular correlations. Am J Med Genet (2002) 2.51
Transgenic mice overexpressing human fibroblast growth factor 23 (R176Q) delineate a putative role for parathyroid hormone in renal phosphate wasting disorders. Endocrinology (2004) 2.40
Preparation and structural characterization of large heparin-derived oligosaccharides. Glycobiology (1995) 2.12
The autosomal dominant hypophosphatemic rickets R176Q mutation in fibroblast growth factor 23 resists proteolytic cleavage and enhances in vivo biological potency. J Biol Chem (2003) 1.99
A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.93
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
FGF-23 inhibits renal tubular phosphate transport and is a PHEX substrate. Biochem Biophys Res Commun (2001) 1.90
Fibroblast growth factor (FGF)-23 inhibits renal phosphate reabsorption by activation of the mitogen-activated protein kinase pathway. J Biol Chem (2002) 1.79
Conformational changes and anticoagulant activity of chondroitin sulfate following its O-sulfonation. Carbohydr Res (1998) 1.79
Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities. Mol Cell Biol (1992) 1.77
Proline to arginine mutations in FGF receptors 1 and 3 result in Pfeiffer and Muenke craniosynostosis syndromes through enhancement of FGF binding affinity. Hum Mol Genet (2003) 1.66
Spatial and temporal expression of heparan sulfate in mouse development regulates FGF and FGF receptor assembly. J Cell Biol (2003) 1.55
Selective effects of sodium chlorate treatment on the sulfation of heparan sulfate. J Biol Chem (1999) 1.42
Fibroblast growth factor receptors have different signaling and mitogenic potentials. Mol Cell Biol (1994) 1.40
Chlorate: a reversible inhibitor of proteoglycan sulfation. Biochem Biophys Res Commun (1988) 1.34
Transfer of functional EGF receptors to an IL3-dependent cell line. J Cell Physiol (1988) 1.26
Fibroblast growth factor receptors and their ligands in the adult rat kidney. Kidney Int (2001) 1.06
Fibroblast growth factor 23 reduces expression of type IIa Na+/Pi co-transporter by signaling through a receptor functionally distinct from the known FGFRs in opossum kidney cells. Genes Cells (2005) 1.02
Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans. Int J Biol Macromol (1999) 1.00
Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney. Kidney Int (1999) 0.99
Homogeneous, structurally defined heparin-oligosaccharides with low anticoagulant activity inhibit the generation of the amplification pathway C3 convertase in vitro. J Biol Chem (1988) 0.97
Regulation of endothelin-1 and transforming growth factor-beta1 production in cultured proximal tubular cells by albumin and heparan sulphate glycosaminoglycans. Nephrol Dial Transplant (2001) 0.93
Effect of fully sulfated glycosaminoglycans on pulmonary artery smooth muscle cell proliferation. Arch Biochem Biophys (1999) 0.93
Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21. Cell Metab (2007) 9.62
Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med (2003) 8.87
Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet (2006) 7.53
Heparin-protein interactions. Angew Chem Int Ed Engl (2002) 7.27
The FGF family: biology, pathophysiology and therapy. Nat Rev Drug Discov (2009) 6.23
Receptor specificity of the fibroblast growth factor family. The complete mammalian FGF family. J Biol Chem (2006) 5.78
A twist code determines the onset of osteoblast differentiation. Dev Cell (2004) 5.40
Structural basis for fibroblast growth factor receptor activation. Cytokine Growth Factor Rev (2005) 4.69
Conditional inactivation of FGF receptor 2 reveals an essential role for FGF signaling in the regulation of osteoblast function and bone growth. Development (2003) 4.63
Evolution of the Fgf and Fgfr gene families. Trends Genet (2004) 4.53
The parathyroid is a target organ for FGF23 in rats. J Clin Invest (2007) 4.47
Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am J Surg Pathol (2004) 4.46
Oversulfated chondroitin sulfate is a contaminant in heparin associated with adverse clinical events. Nat Biotechnol (2008) 4.46
Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21. J Biol Chem (2007) 4.42
BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc Natl Acad Sci U S A (2007) 4.00
FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response. Proc Natl Acad Sci U S A (2009) 3.99
Sequential roles of Hedgehog and Wnt signaling in osteoblast development. Development (2004) 3.89
Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol Cell Biol (2007) 3.73
FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Invest (2003) 3.60
Twist regulates cytokine gene expression through a negative feedback loop that represses NF-kappaB activity. Cell (2003) 3.40
Digenic mutations account for variable phenotypes in idiopathic hypogonadotropic hypogonadism. J Clin Invest (2007) 3.20
Cellular binding of hepatitis C virus envelope glycoprotein E2 requires cell surface heparan sulfate. J Biol Chem (2003) 2.94
Impaired FGF signaling contributes to cleft lip and palate. Proc Natl Acad Sci U S A (2007) 2.94
Conserved roles for Slit and Robo proteins in midline commissural axon guidance. Neuron (2004) 2.94
Endocardial and epicardial derived FGF signals regulate myocardial proliferation and differentiation in vivo. Dev Cell (2005) 2.93
Lessons learned from the contamination of heparin. Nat Prod Rep (2009) 2.81
Chemoenzymatic synthesis of homogeneous ultralow molecular weight heparins. Science (2011) 2.79
A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis. J Clin Invest (2007) 2.79
Inhibition of growth hormone signaling by the fasting-induced hormone FGF21. Cell Metab (2008) 2.76
Coordination of chondrogenesis and osteogenesis by fibroblast growth factor 18. Genes Dev (2002) 2.75
Fibroblast growth factors: from molecular evolution to roles in development, metabolism and disease. J Biochem (2010) 2.70
A molecular brake in the kinase hinge region regulates the activity of receptor tyrosine kinases. Mol Cell (2007) 2.70
Decreased FGF8 signaling causes deficiency of gonadotropin-releasing hormone in humans and mice. J Clin Invest (2008) 2.69
Research resource: Comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol Endocrinol (2010) 2.67
Fibroblast growth factor signals regulate a wave of Hedgehog activation that is essential for coronary vascular development. Genes Dev (2006) 2.56
Functional evolutionary history of the mouse Fgf gene family. Dev Dyn (2008) 2.43
FGF9 and FGF20 maintain the stemness of nephron progenitors in mice and man. Dev Cell (2012) 2.43
Fibroblast growth factor 21 promotes bone loss by potentiating the effects of peroxisome proliferator-activated receptor γ. Proc Natl Acad Sci U S A (2012) 2.38
Interaction of FGF, Ihh/Pthlh, and BMP signaling integrates chondrocyte proliferation and hypertrophic differentiation. Dev Cell (2002) 2.37
Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A (2011) 2.24
Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation. Proc Natl Acad Sci U S A (2009) 2.23
FGF22 and its close relatives are presynaptic organizing molecules in the mammalian brain. Cell (2004) 2.20
The proteoglycan bikunin has a defined sequence. Nat Chem Biol (2011) 2.14
Structural basis by which alternative splicing modulates the organizer activity of FGF8 in the brain. Genes Dev (2005) 2.10
Fibroblast growth factor 14 is an intracellular modulator of voltage-gated sodium channels. J Physiol (2005) 2.05
In vivo genetic evidence for klotho-dependent, fibroblast growth factor 23 (Fgf23) -mediated regulation of systemic phosphate homeostasis. FASEB J (2008) 2.03
Solution structures of chemoenzymatically synthesized heparin and its precursors. J Am Chem Soc (2008) 2.02
Flexible energy storage devices based on nanocomposite paper. Proc Natl Acad Sci U S A (2007) 2.02
Current status of surgery in dermatology. J Am Acad Dermatol (2013) 1.98
FGF9 and SHH signaling coordinate lung growth and development through regulation of distinct mesenchymal domains. Development (2006) 1.94
A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis. J Clin Endocrinol Metab (2005) 1.93
Abnormalities in cartilage and bone development in the Apert syndrome FGFR2(+/S252W) mouse. Development (2005) 1.93
Biochemical analysis of pathogenic ligand-dependent FGFR2 mutations suggests distinct pathophysiological mechanisms for craniofacial and limb abnormalities. Hum Mol Genet (2004) 1.92
Mutations that cause osteoglophonic dysplasia define novel roles for FGFR1 in bone elongation. Am J Hum Genet (2004) 1.92
Ataxia and paroxysmal dyskinesia in mice lacking axonally transported FGF14. Neuron (2002) 1.91
Exploring mechanisms of FGF signalling through the lens of structural biology. Nat Rev Mol Cell Biol (2013) 1.90
Electron detachment dissociation of glycosaminoglycan tetrasaccharides. J Am Soc Mass Spectrom (2006) 1.89
Enzymatic redesigning of biologically active heparan sulfate. J Biol Chem (2005) 1.89
Development of the endochondral skeleton. Cold Spring Harb Perspect Biol (2013) 1.89
Mutations in fibroblast growth factor receptor 1 cause both Kallmann syndrome and normosmic idiopathic hypogonadotropic hypogonadism. Proc Natl Acad Sci U S A (2006) 1.87
Fibroblast growth factor (FGF) homologous factors share structural but not functional homology with FGFs. J Biol Chem (2003) 1.86
Fibroblast growth factor homologous factors control neuronal excitability through modulation of voltage-gated sodium channels. Neuron (2007) 1.84
Circulating αKlotho influences phosphate handling by controlling FGF23 production. J Clin Invest (2012) 1.80
FGF23 and disorders of phosphate homeostasis. Cytokine Growth Factor Rev (2005) 1.79
FGF23 is processed by proprotein convertases but not by PHEX. Bone (2004) 1.79
An FGF-WNT gene regulatory network controls lung mesenchyme development. Dev Biol (2008) 1.78
Initial FGF23-mediated signaling occurs in the distal convoluted tubule. J Am Soc Nephrol (2009) 1.74
The FGF14(F145S) mutation disrupts the interaction of FGF14 with voltage-gated Na+ channels and impairs neuronal excitability. J Neurosci (2007) 1.74